Literature DB >> 12721699

Features of cell death in brain and liver, the target tissues of progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher disease).

Alessandro Simonati1, Massimiliano Filosto, Chiara Savio, Giuliano Tomelleri, Paola Tonin, Bernardo Dalla Bernardina, Nicolo' Rizzuto.   

Abstract

Alpers-Huttenlocher disease (AHD) is a rare encephalopathy of infancy and childhood characterized by myoclonic seizures and progressive neurological deterioration, usually associated with signs and symptoms of liver dysfunction. There is no biological marker of the disease, and ultimate diagnosis still relies on pathological examination. Features of clinical progression and pathological findings suggest AHD to be secondary to a genetically determined disorder of mitochondrial function. We report on four AHD patients and focus on their pathological features in brain, liver and muscle. Liver and muscle biopsy specimens were examined using histochemical markers of the oxidative pathways, probes to immunodetect molecules of the apoptotic cascades and electron microscopy. In liver (but not in muscle) biopsy samples, activated caspases were detected by immunohistochemistry: foci of caspase-9-positive cells were seen in a child affected with chronic, progressive fibrosis. In an 18-year-old boy, who suffered from valproic acid-associated acute hepatitis, caspase-3 cells were clustered among the necrotic foci and the foamy cells. In both patients electron microscopy revealed apoptotic nuclei. Normal muscle biopsy specimens were observed in two children, 2 and 8 years-old respectively; in the 18-year-old patient cytochrome oxidase-negative fibers as well as ultrastructural findings of mitochondrial abnormalities were observed. In no patient was there biochemical evidence of impaired oxidative metabolism. Neuropathological examination of the brains of two patients (13 months and 19 years old, respectively) showed focal distribution of the lesions affecting the telencephalic cortex and, to a lesser extent, subcortical gray nuclei. Along with the necrotizing lesions, characterized by neuronal loss, neuropil microcysts and newly formed vessels, we also observed acutely shrunken neurons and features of apoptotic cell death in the cerebral cortex only. Severe neuronal loss without necrotizing features was observed in the cerebellar cortex. The presence of both anoxic and apoptotic nuclei in brain and liver, the target tissues of the disease, is consistent with the hypothesis that abnormal activation of mitochondrion-related cell death pathways might be involved in the pathogenesis of AHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721699     DOI: 10.1007/s00401-003-0698-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  6 in total

Review 1.  Alpers-Huttenlocher syndrome.

Authors:  Russell P Saneto; Bruce H Cohen; William C Copeland; Robert K Naviaux
Journal:  Pediatr Neurol       Date:  2013-03       Impact factor: 3.372

2.  Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains.

Authors:  Chalon R Majewski-Tiedeken; Cara R Rabin; Steven J Siegel
Journal:  Drug Alcohol Depend       Date:  2007-10-24       Impact factor: 4.492

Review 3.  Alpers-Huttenlocher syndrome: the role of a multidisciplinary health care team.

Authors:  Russell P Saneto
Journal:  J Multidiscip Healthc       Date:  2016-07-26

Review 4.  Gastrointestinal manifestations of mitochondrial disorders: a systematic review.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Therap Adv Gastroenterol       Date:  2016-10-06       Impact factor: 4.409

Review 5.  Mitochondrial Neurodegeneration.

Authors:  Massimo Zeviani; Carlo Viscomi
Journal:  Cells       Date:  2022-02-11       Impact factor: 6.600

Review 6.  Metabolic Dysfunction and Oxidative Stress in Epilepsy.

Authors:  Jennifer N Pearson-Smith; Manisha Patel
Journal:  Int J Mol Sci       Date:  2017-11-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.